Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 13, 2024

Pegargiminase Plus First-Line Chemotherapy for Nonepithelioid Pleural Mesothelioma

JAMA Oncology

 

Additional Info

JAMA Oncology
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial
JAMA Oncol 2024 Feb 15;[EPub Ahead of Print], PW Szlosarek, BC Creelan, T Sarkodie, L Nolan, P Taylor, O Olevsky, F Grosso, D Cortinovis, M Chitnis, A Roy, D Gilligan, H Kindler, D Papadatos-Pastos, GL Ceresoli, AS Mansfield, A Tsao, KJ O'Byrne, AK Nowak, J Steele, M Sheaff, CF Shiu, CL Kuo, A Johnston, J Bomalaski, MG Zauderer, DA Fennell

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading